What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is IV administered at Visit 2, and \[F-18\]Florastamin PET/CT images are obtained from the head to thigh after 110 ± 10 minutes.”In the company’s words, NCT05004285 on ClinicalTrials.gov
- Tested for
- High Risk Prostate Carcinoma (2 trials)
- Main trialPhase 3
- “Only in subjects who satisfy the inclusion/exclusion criteria, a single dose of \[F-18\]Florastamin at 10 ± 1 mCi is IV administered at Visit 2, and \[F-18\]Florastamin PET/CT images are obtained from the head to thigh after 110 ± 10 minutes.”In the company’s words, NCT05004285 on ClinicalTrials.gov
Other drugs for High Risk Prostate Carcinoma
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 1 Jun 2025 | Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis | |
| Phase 3Active, not recruiting | Jun 2025 | [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer | |
| Phase 3Completed | 16 Apr 2026 | Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer | |
| Phase 3Completed | 11 Jun 2026 | Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026